We investigated the enzyme kinetic basis for the stereoselective disposition of R-and S-omeprazole (OME) and racemic OME in human liver microsomes. OME is primarily metabolized by the hepatic cytochrome P450 enzyme system (CYP2C19 and 3A4). The metabolism of each enantiomer and pseudoracemic OME was studied using unlabeled and 13 C 7 -labeled enantiomers. The enantiomers inhibited each other's metabolism competitively in human liver microsomes and in recombinant CYP2C19 and 3A4. The results obtained with the individual enantiomers allowed successful prediction of the enzyme kinetics for the pseudoracemate. The intrinsic clearance of each enantiomer in a pseudoracemic mixture remained the same as those of the individually incubated enantiomers, although K m and V max decreased. In the pseudoracemate, the relative contribution of CYP2C19 and 3A4 to 5-hydroxylation and 5Ј-O-demethylation of R-OME was comparable to that obtained for the incubation of R-OME alone. For S-OME, however, the presence of its antipode greatly increased the contribution of CYP3A4, with increasing concentrations, compared with that obtained when incubating S-OME alone. The results of our in vitro study clearly show metabolic interactions between the OME enantiomers, which may also occur in vivo. Because the enantiomers of OME produce similar pharmacological effects, the enantiomer interactions should not significantly affect the pharmacodynamics. On the other hand, the use of the S-enantiomer results in less complex enzyme kinetics than those of the racemate; thus, the outcome of its clinical use is more predictable.
relative contribution of CYP2C19 and 3A4 to 5-hydroxylation and 5Ј-O-demethylation of R-OME was comparable to that obtained for the incubation of R-OME alone. For S-OME, however, the presence of its antipode greatly increased the contribution of CYP3A4, with increasing concentrations, compared with that obtained when incubating S-OME alone. The results of our in vitro study clearly show metabolic interactions between the OME enantiomers, which may also occur in vivo. Because the enantiomers of OME produce similar pharmacological effects, the enantiomer interactions should not significantly affect the pharmacodynamics. On the other hand, the use of the S-enantiomer results in less complex enzyme kinetics than those of the racemate; thus, the outcome of its clinical use is more predictable.
Omeprazole (OME), a proton pump inhibitor (PPI), has been widely used for many years as an acid inhibitory agent for the treatment of gastric acid hypersecretion disorders. OME is a chiral compound and the sulfinyl group is the chiral center ( Fig. 1) . It is administered as a racemic (50/50) mixture of the S-and R-enantiomers. Recently, its optical Sisomer has been developed as a new drug (esomeprazole). OME as well as its enantiomers are prodrugs with a common mechanism of action involving chemical rearrangement to a pharmacologically active achiral sulfenamide in the acidic compartment of parietal cells (Lindberg et al., 1986) . The formed sulfenamide reacts with sulfhydryl groups of the enzyme H ϩ ,K ϩ -ATPase (the proton pump), which is located in the canaliculi of the parietal cells, thus inhibiting its ability to participate in gastric acid formation. OME and its enantiomers are thus equally potent H ϩ ,K ϩ -ATPase inhibitors (Andersson et al., 2001 ). However, R-and S-OME show stereoselective disposition because of the enzyme-catalyzed stereoselective metabolism that leads to the higher metabolic stability of esomeprazole compared with its R-isomer and the racemate, which has been demonstrated in vitro using human liver microsomes (Äbelö et al., 2000) . The resulting increase in drug exposure in the majority of the population, as indicated by the higher area under the plasma concentration-time curve after esomeprazole administration, provides more effective control of gastric acid secretion than that of the other PPIs (lansoprazole, pantoprazole, and rabeprazole) when given at their standard doses (Lindberg et al., 2003; Miner et al., 2003) . OME and its enantiomers are extensively metabolized in the liver by the cytochrome P450 (P450) enzyme system and the major metabolites formed are 5Ј-O-desmethylOME, 5-and 3-hydroxyOME (5-and 3-OH-OME), and OME sulfone (Renberg et al., 1989; Andersson et al., 2001) (Fig. 1) . These metabolites do not contribute to the pharmacological effect (B. Wallmark and J. Fryklund, data on file at AstraZeneca). Formation of the sulfone metabolite and 3-OH-OME is mediated by CYP3A4, whereas 5-OH-OME and 5Ј-O-desmethylOME are mainly formed by CYP2C19 with some contribution from CYP3A4. Previous in vitro studies have shown that R-OME is cleared efficiently via CYP2C19 with minor contribution from CYP3A4, whereas the reverse P450 contribution was found for the S-isomer but with relatively lower clearance (Äbelö et al., 2000) . This difference in enzyme kinetic properties between the two enantiomers in vitro is in agreement with stereoselective pharmacokinetics of the OME enantiomers in vivo (Tybring et al., 1997) . The total system clearance (CL/F) of R-OME was approximately 1.4-fold higher than for S-OME after oral administration of racemic OME in CYP2C19 extensive metabolizers (EMs). In another study, the total system clearance of R-OME was 1.9-fold higher than that for S-OME in EMs, after separate oral administration of R-and S-OME (Andersson et al., 2001) . This difference in pharmacokinetic and enzyme kinetic characteristics prompted us to investigate the enantiomer/enantiomer interactions between R-and S-OME in detail using current in vitro technologies.
The aim of this work was to characterize the interactions between the enantiomers of OME, with respect to their four metabolic reactions. A detailed investigation of the enantiomer/enantiomer interactions on the formation rates of OME enantiomer metabolites and the contribution of individual P450 enzymes was made possible by using S-[ 13 C 7 ]OME and unlabeled R-OME and subsequently, LC/MS/MS analysis. A thorough analysis was made of the enzyme reactions according to kinetic models describing competition of enzyme activities toward a racemic mixture when the enantiomers are substrates to the same enzymes. Because racemic OME is used clinically, in vitro catalytic data on the racemic substrate and the individual enantiomers can be used to explain the in vitro-in vivo correlation of the metabolism of OME reported in humans. The maximum plasma concentrations after therapeutically relevant repeated doses of OME racemate in CYP2C19 EMs and poor metabolizers (PMs) were 1 and 3 M, respectively, and 5 and 7 M esomeprazole in EMs and PMs, respectively (Li et al., 2004) . Thus, this clinically relevant substrate concentration range has been included in our study.
Materials and Methods
Chemicals and Reagents. Racemic OME sodium (rac-5Ј-methoxy-2Ј-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt) was obtained from AstraZeneca Bulk Production (Södertä lje, Sweden). S-OME sodium and R-OME sodium were obtained from AstraZeneca Process R&D (Södertä lje, Sweden). S-[ 13 C 7 ]OME potassium (see Fig. 1 for the positions of the 13 C labels; the full synthesis description can be found online as Supplemental Data), OME sulfone (5Ј-methoxy-2Ј-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole), and racemic 5Ј-O-desmethylOME (rac-5Ј-hydroxy-2Ј-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole) were obtained from Medicinal Chemistry (AstraZeneca R&D Mö lndal, Sweden). Racemic 5-OH-OME (rac-5Ј-methoxy-2Ј-[[(4-methoxy-3-methyl-5-hydroxymethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole) was obtained from Synthelec AB (Lund, Sweden). Tinidazole (internal standard) and NADPH were purchased from SigmaAldrich (St. Louis, MO). The enantiomeric purity of each OME enantiomer was Ͼ99%. All other chemicals and reagents were of the highest commercially available quality.
Human Liver Microsomes (HLM) and Recombinant Cytochrome P450s. Human liver samples (excess liver tissue removed during surgery on the liver) were obtained from Sahlgrenska Hospital (Göteborg, Sweden). All tissues were obtained by qualified medical staff, with donor consent and with the approval of the local ethics committee at Sahlgrenska Hospital. HLM were prepared from 20 liver samples obtained from male and female patients (Caucasian) according to the method of Ernster et al. (1962) . A pool was prepared by mixing equal volumes of each individual liver microsomal preparation, with similar protein content, to reflect the average P450 activities in humans. Recombinant human CYP2C19 and 3A4 (rCYP2C19 and rCYP3A4) were heterologously expressed in Saccharomyces cerevisiae and obtained from AstraZeneca Biotech Laboratory (Södertä lje, Sweden) (Masimirembwa et al., 1999) . Microsomal protein concentration was measured according to Lowry et al. (1951) using bovine serum albumin as the standard. The microsomal preparations were stored at Ϫ80°C until use.
Incubation of Omeprazole Enantiomers and Pseudoracemate with HLM and rCYP2C19 and 3A4. The in vitro incubation system consisted of HLM (0.3 mg/ml of protein or rCYP2C19/3A4 with 50 pmol/ml), OME R-and S-enantiomers, or the mixture of equal or unequal mole fractions of S-[ 13 C 7 ]OME and R-OME, and 1 mM NADPH dissolved in 0.1 M Tris-hydrochloride buffer, pH 7.4, in a final volume of 200 l. All incubations were conducted at 37°C for 20 min. Linear conditions for the formation rate of 5-and 3-OH-OME, 5Ј-O-desmethylOME and OME sulfone were evaluated with respect to protein content and incubation time. The optimum conditions, as described above, were selected for the kinetic study. All reactions were performed in 96-well plates. The metabolic reactions were started by addition of NADPH after a preincubation of 5 min at 37°C, and terminated by the addition of an aliquot of 100 l of ice-cold acetonitrile (containing 1.5 M internal standard). After centrifugation at 4500g for 20 min, 20 l of supernatant was injected into the LC/MS/MS system. Samples were quantified by monitoring the ratio between the metabolites of the enantiomers of OME and the internal standard in each sample and in calibration curves. All incubations throughout the study were carried out in duplicate. For each incubation, the test compounds were dissolved in methanol and sequentially diluted with 40% of methanol in 0.1 M Tris-hydrochloride buffer, pH 9. The final pH value of the incubation mixture was kept at 7.4 and the methanol concentration was less than 1%. The formation kinetics of 5Ј-O-desmethylOME, 5-and 3-OH-OME and OME sulfone were determined at substrate concentrations ranging from 1 to 128 M (OME enantiomers and equimolar pseudoracemate). Control experiments excluded unusual enzyme kinetic behavior, especially substrate inhibition, at concentrations up to 750 and 400 M, for rCYP3A4 and rCYP2C19, respectively. The inhibition experiments were performed using R-OME as an inhibitor of the metabolism of S-[ 13 C 7 ]OME, and vice versa. The substrate concentrations were chosen with regard to the Michaelis-Menten kinetics (K m and V max ) for each metabolic reaction (Table 1 ) (approximately 0.5 K m , K m , 3 K m , and 5 K m ; when two enzyme systems were involved, the high affinity K m1 was used). The inhibitor concentrations were varied from 1 to 150 M at four different concentrations selected on the basis of the IC 50 values obtained previously (approximately 0.5ϫ IC 50 , IC 50 , 2ϫ IC 50 , and 4ϫ IC 50 ).
High-Performance Liquid Chromatography Conditions. The high-performance liquid chromatography system used included a Surveyor MS pump, a built-in degasser, a Surveyor PDA detector (Thermo Electron Corporation, Waltham, MA) and a CTC HTS autosampler (CTC Analytics, Zwingen, Switzerland). Chromatography was performed on an Eclipse XDB-C8 column (4.6 ϫ 150 mm, 5 m; Agilent, Palo Alto, CA) with an Eclipse XDB-C8 guard column (4.6 ϫ 12.5 mm, 5 m). The mobile phases consisted of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B), which increased linearly from 25% of solvent B to 65% B during 5 min at a flow rate of 0.8 ml/min. The effluent was split with approximately 0.3 ml/min being introduced into the mass spectrometer. The Surveyor PDA detector was set at 302 nm to monitor the consumption of the substrates, which was less than 20% of their initial concentrations after incubation. The chiral stability of the enantiomers of OME in HLM and rCYP2C19 and 3A4 was also estimated using chiral LC/MS/MS analysis (data not shown). Negligible amounts (Ͻ0.3%) of the optical antipode were detected during incubation of the individual enantiomers of OME at a concentration of 50 M for 20 min. Thus, the enantiomers of OME are optically stable under the experimental conditions in this study.
Mass Spectrometric Conditions. The mass spectrometric analyses were performed using a TSQ Quantum triple quadrupole mass spectrometer (Thermo Electron Corporation). The mass spectrometer was operated in the positive ionization electrospray mode, and the instrument settings were optimized using the analytes. The mass spectrometer was operated in the selected reaction monitoring mode. The selected reaction monitoring transitions of the [M ϩ H] ϩ precursor ions to selected product ions were monitored for the analytes and internal standard with the following typical values: 5-and 3-OH-OME as well as OME sulfone m/z 362.1 to 214.0 (collision energy, 22 eV); their respective 13 C 7 -labeled metabolites m/z 369.1 to 214.0 (collision energy, 22 eV); 5Ј-O-desmethylOME m/z 332.1 to 198.0 (collision energy 16 eV); 5Ј-O-[ 13 C 6 ]desmethylOME m/z 338.1 to 198.0 (collision energy, 16 eV), and internal standard tinidazole m/z 248.0 to 121.0 (collision energy, 22 eV). Instrument control, data acquisition, and data evaluation were performed using Xcalibur software (version 1.3; Thermo Electron Corporation). Quantitation of 13 C-labeled metabolites was based on the calibration standards prepared by using the unlabeled reference compounds. Because of the lack of synthetic 3-OH-OME standard, the quantitation of this metabolite was evaluated by using 5-OH-OME as the reference. The lower limit of quantification was 5 nM for all the analytes.
Relative Contributions of CYP2C19 and 3A4 to OME 5-ODemethylation and 5-Hydroxylation in HLM. Our previous studies demonstrated that CYP2C19 and 3A4 are the major enzymes responsible for 5Ј-O-demethylation and 5-hydroxylation of the OME enantiomers (Äbelö et al., 2000) . A relative activity factor (RAF) approach (Crespi, 1995; Störmer et al., 2000) was used to estimate the relative contributions of P450s (RC i of CYP2C19 and 3A4) on the metabolism of the individual OME enantiomers in HLM, in the absence or presence of the optical antipode. RAF i values for CYP2C19 (24.8 pmol of rCYP2C19/mg HLM) and CYP3A4 (248.1 pmol of rCYP3A4/mg HLM) were obtained from our previous study (Li et al., 2003) , where they were determined as the ratio of the activity of each enzyme marker reaction in HLM and recombinant P450s. The P450 enzyme specific marker reactions used for CYP2C19 and 3A4 were S-mephenytoin 4Ј-hydroxylation and midazolam 1Ј-hydroxylation, respectively. The individual rCYP i reaction velocity v r i (S) at each substrate concentration, [S] , was obtained using the Michaelis-Menten equation (eq. 1). RAF i values for each respective CYP i were entered with v r i (S) in eqs. 2 and 3 to estimate the total activity in HLM (v) contributed by the P450s investigated and the relative contribution by each respective CYP i (RC i ).
Enzyme Kinetics of R-and S-Enantiomers as Competing Substrates in a Racemic Mixture (50:50). The enzyme kinetics for competitive interaction between enantiomers during the metabolism of a pseudoracemic substrate is a special case of competitive inhibition as has been described in detail by Kim et al. (1993) . For a reaction catalyzed by a single enzyme, the apparent Michaelis-Menten constants of the R-and S-enantiomers in a racemic mixture are related to their respective true V max and K m by an offset containing the ratio of the true K m values of the enantiomers. This is illustrated by the following equations for the R-enantiomer:
where [R] is the concentration of the R-enantiomer in a racemate. The equations for the S-enantiomer in a racemate can be derived in the same way. Therefore, the apparent V max app and K m app of both enantiomers are lower than their respective true values, whereas the clearance of the enantiomers in a racemate is still equal to their true value (eq. 7, i.e., V max /K m ). It can readily be shown that the R/S ratio of the apparent K m app for the enantiomers in a racemate is equal to 1; i.e., K m,R app ϭ K m,S app . On the other hand, the values of the R/S ratios of the apparent V max app as well as the metabolite formation velocities (v app ) are equal to the ratio of the true intrinsic clearance (i.e., V max /K m ) of the enantiomers. Hence, the ratio of the apparent V max app fully reflects the enantioselectivity of the enzymatic reaction, and the v R app /v S app ratio is a constant that does not depend on the substrate concentration. Deviation from this consistency in the v R app /v S app ratio over a range of substrate concentrations may reflect the contribution of multiple enzymes to the formation of a given metabolite with differing K m values and enantioselectivities.
Data Analysis. Enzyme kinetic parameters (K m , V max , and K i ) and inhibition mechanisms were analyzed using nonlinear leastsquares regression by fitting different models of the enzyme kinetic and inhibition data using the SigmaPlot Enzyme Kinetics Module for Kinetic parameters for omeprazole racemate and enantiomers with respect to the four major metabolic reactions, 5Ј-O-demethylation, 5-and 3-hydroxylation, and sulfoxidation, in human liver microsomes and rCYP2C19 and 3A4
The predicted apparent K m and V max values of OME enantiomers in racemate using a model of competitive interaction of enantiomers in racemate are shown in parentheses. The enantiomer data are obtained from incubation of enantiomers individually or in pseudoracemate. Microsome
Compound 5-Hydroxylation S-OME Windows 7.0 (SPSS Inc., Chicago, IL). The model with the best fit was selected based on the dispersion of residuals and the Akaike Information Criterion (Yamaoka et al., 1978) . The intrinsic clearance (CL int ) is given as V max /K m for single enzyme kinetics and V max1 /K m1 ϩ V max2 /K m2 for the two-isoenzyme system.
Results
Identification of Metabolites of OME Enantiomers. Control incubations showed that the metabolite formation required microsomal enzymes and NADPH. In HLM, four oxidized metabolites were formed after incubation with OME enantiomers. Three of the metabolites were identified as 5Ј-O-desmethylOME, 5-OH-OME, and OME sulfone by comparing them with synthetic reference compounds. The other hydroxylated metabolite was identified as 3-OH-OME in accordance with previous studies (L. Weidolf, data on file at AstraZeneca). rCYP3A4 catalyzed the formation of all four metabolites, whereas rCYP2C19 only catalyzed 5-hydroxylation and 5Ј-O-demethylation.
Stereoselective Metabolism Kinetics of Omeprazole Enantiomers in HLM and Recombinant CYP2C19 and 3A4. Eadie-Hofstee plots for the formation kinetics of the metabolites of OME in HLM (plots not shown) indicated that 3-hydroxylation and sulfoxidation were performed by a single enzyme, whereas 5Ј-O-demethylation and 5-hydroxylation seemed to involve multiple P450 enzymes. Consequently, the experimental data were evaluated using the single or twoenzyme Michaelis-Menten models that best described the kinetics for the individual metabolites. Pronounced enantioselectivity for 5-hydroxylation, 5Ј-O-demethylation and sulfoxidation was observed after incubation of the individual enantiomers in HLM (Table 1) . Regarding 5-hydroxylation, R-OME showed a 5-fold lower K m1 than the S-isomer in HLM and the corresponding CL int was 7-fold higher. On the other hand, S-OME exhibited 2-and 3-fold higher CL int of 5Ј-Odemethylation and sulfoxidation, respectively, than for the R-isomer. Consequently, the total CL int of R-OME in HLM was 2.2-fold higher than that of the S-isomer. Similar stereoselectivity was also observed when the pseudoracemate (50: 50) was used as substrate, with the result that the total apparent CL int of R-OME in HLM was 1.5-fold higher than that of S-isomer. The values of CL int for OME racemate, i.e., the equimolar mixture of the R-and S-enantiomers, were in between the values of those for the individual enantiomers (Table 1) . In agreement with previous data (Äbelö et al., 2000) , the enzyme kinetic parameters obtained from rCYP2C19 and rCYP3A4 confirmed that the metabolic reactions of OME enantiomers obey simple Michaelis-Menten kinetics and these two enzymes are the main contributors to the stereoselective metabolism of the OME enantiomers. CYP2C19 favors R-OME for 5-hydroxylation and S-OME for 5Ј-O-demethylation, whereas CYP3A4 favors R-OME for 5-hydroxylation and S-OME for 5Ј-O-demethylation as well as 3-hydroxylation and sulfoxidation. When OME pseudoracemate was incubated in HLM or rCYPs, the apparent K m app and V max app values for the formation of each metabolite from the enantiomers were lower compared with incubation with the individual enantiomers, indicating interactions between the two enantiomers. Representative Michaelis-Menten curves are depicted in Figs. 2 through 4.
Results obtained after incubation of S-[ 13 C 7 ]OME in a separate experiment were identical to those obtained after incubation of the unlabeled S-enantiomer (data not shown). Therefore, isotope effects on the formation of metabolites of the labeled S-isomer could be excluded. Inhibition Studies. The inhibition potential of one OME enantiomer on the metabolic reactions of its optical antipode was investigated in HLM and rCYP2C19 and 3A4 using unlabeled R-OME and 13 C-labeled S-OME as substrate and inhibitor, respectively, and vice versa. Formation of unlabeled and labeled metabolites from R-and S-[ 13 C 7 ]OME was measured separately. The apparent inhibition constants (K i ) for the formation of each metabolite of the OME enantiomers were calculated using the competitive inhibition model that provided the best fit. The results are summarized in Table 2 . Figure 5 shows Dixon plots for the inhibition of R-or S-[ 13 C 7 ]OME 5-hydroxylase activities by their respective optical antipode in HLM and rCYP2C19.
R-OME 5-hydroxylation and 5Ј-O-demethylation activities were inhibited by the S-isomer in HLM exhibiting the K i values of 11.3 and 27.9 M, respectively, which is in agreement with that obtained in rCYP2C19 (11.6 and 13.3 M, respectively). This suggests that these two metabolic reactions of R-OME are mainly catalyzed by CYP2C19 and are competitively inhibited by the S-isomer. The inhibitory effect of R-OME on the 5-hydroxylation and 5Ј-O-demethylation of S-[ 13 C 7 ]OME, however, was much less potent in HLM (K i values of 42.1 and 28.9 M, respectively) than in rCYP2C19 (K i values of 1.2 and 1.3 M, respectively). The inhibitory potency of R-OME on the 3-hydroxylation and sulfoxidation of S-[ 13 C 7 ]OME was poorer than that of S-OME on the same reactions of the R-isomer, in both rCYP3A4 and HLM. The CYP3A4 catalyzed 5-hydroxylation and 5Ј-O-demethylation of the OME enantiomers was poorly affected by their antipodes, exhibiting K i values more than 60 M.
Competitive Interaction Model of Enzyme Kinetics of OME Enantiomers in Racemate. The OME enantiomers interacted competitively on CYP2C19 and 3A4. Pre- jpet.aspetjournals.org dictions of their respective enzyme kinetics in racemate catalyzed by the single enzymes rCYP2C19 or rCYP3A4 were performed based on the kinetic parameters of the individual OME enantiomers and the kinetic model for competitive interaction between enantiomers in a racemic substrate (Kim et al., 1993) (equations are given under Materials and Methods) . The predicted values of the enzyme kinetics (apparent K m app , V max app , and CL int app ) for the individual enantiomers in the racemic mixture were in good agreement with those observed when analyzed stereoselectively in a pseudoracemate incubation (Table 1; Fig. 6 ), giving reduced apparent V max app and K m app that resulted in unchanged intrinsic clearances for the enantiomers in the pseudoracemate compared with those of the enantiomers when incubated individually. The most striking effect was the more than 7-fold decrease in V max and K m of S-OME 5-hydroxylation in the presence of equal amounts of R-OME in rCYP2C19, which is consistent with the predicted values given by the competitive interaction model (Table 1) . The R/S ratios of the predicted and observed apparent V max app of 5-hydroxylation (11.8 and 12.8, respectively) agreed with the ratio of their intrinsic clearances for the individual incubation of the enantiomers as well as for the pseudoracemate (value of 11.8), as predicted by eqs. 5 and 7. The predicted kinetics of R-and S-OME 5-hydroxylation by rCYP2C19 in the presence of their respective antipode at different concentrations is illustrated in Fig. 6 . The solid line represents the enzyme kinetics of the substrate in the presence of equal concentrations of the competitive inhibitor in (Fig. 6) fit well with the observed data in the pseudoracemate (Fig. 3) except that the activities of R-OME was somewhat lower than the predicted values at concentrations higher than 60 M. However, when the pure R-OME enantiomer was incubated the Michaelis-Menten kinetic model describes the 5-hydroxylase activity well even at high concentration. The same observation was also found for S-OME 5Ј-O-demethylation in the pseudoracemate compared with the individual enantiomer in rCYP2C19. Whether these deviations are due to enantiomer/enantiomer interactions only, or if other mechanisms also contribute, remains to be studied.
The ratios for the metabolite formation velocities (v R /v S ) of the enantiomers at different substrate concentrations are shown in Fig. 7 . 5Ј-O-Demethylation by rCYP2C19 exhibited the highest stereoselectivity and the formation of 3-OH-OME the lowest stereoselectivity in HLM. When the individual enantiomers were incubated with rCYP2C19, the v R /v S ratio for the formation of 5-OH-OME decreased significantly as substrate concentrations were increased, whereas this decrease was not prominent in HLM or rCYP3A4. As predicted by the competitive interaction model, the v R /v S ratios of the single rCYP-catalyzed reactions were independent of the substrate concentration when the pseudoracemate was studied but not necessarily with the same pattern when the enantiomers were incubated individually (Fig. 7) . When incubated as a pseudoracemate in HLM, the v R /v S ratios of OME 3-hydroxylation and sulfoxidation were also less affected by the substrate concentration, suggesting that a single enzyme was involved in the reaction. However, the v R /v S ratios for OME 5-hydroxylation and 5Ј-O-demethylation changed with the substrate concentration, indicating the involvement of multiple enzymes with different enzyme affinities and stereoselectivities. In agreement with the prediction, at low substrate concentrations the v R /v S ratios of all the four metabolic reactions of OME were close to the R/S ratio of the respective CL int values for the enantiomers individually as well as for the pseudoracemate.
Relative Contribution of CYP2C19 and CYP3A4 to Omeprazole 5-Hydroxylase and 5-O-Demethylase Activities in HLM. Because two enzyme systems are involved in OME 5-hydroxylation and 5Ј-O-demethylation in HLM, the relative contribution of CYP2C19 and 3A4 for these two metabolic reactions of S-and R-OME were estimated using enzyme kinetic parameters obtained from rCYPs with the RAFs obtained previously (Li et al., 2003) (Fig. 8) . According to this approach, CYP2C19 was found to be dominant over CYP3A4 in catalyzing 5-hydroxylation and 5Ј-O-demethylation of the individual OME enantiomers at low substrate concentration. However, with increasing substrate concentration, the contribution of CYP2C19 decreased continuously with a concomitant increase in the contribution by CYP3A4. For R-OME 5-hydroxylation, the contribution of CYP2C19 decreased from 89% at 1 M to 41% at 128 M, and for S-OME 5-hydroxylation the change was from 79 to 51% over the same concentration range. Furthermore, the relative contribution of the two P450s on the metabolism of one enantiomer in the presence of its antipode was studied using OME pseudoracemate. Interestingly, the relative contribution of CYP2C19 for S-[ 13 C 7 ]OME 5-hydroxylation decreased from 76 to 19% at increasing substrate concentrations with equimolar concentrations of R-OME, and the contribution of CYP3A4 increased up to 80%, with a switch point for CYP3A4 to dominate the metabolic activity over CYP2C19 at equimolar enantiomer concentrations of approximately 8 M. A less but significant effect was also observed on S-[ 13 C 7 ]OME 5Ј-O-demethylation. However, the P450 contribution profiles did not change significantly for 5-hydroxylation and 5Ј-O-demethylation of R-OME in the presence of S-[ 13 C 7 ]OME in the pseudoracemic mixture.
Discussion
The administration of racemic drugs has received considerable attention over the past decade (Hutt and Tan, 1996; Islam et al., 1997) . Differences in overall disposition of enantiomers can arise from stereoselective metabolism and inhibition of each other's metabolism. In the latter case, the enantiomers can compete for the same metabolizing enzymes, which affect elimination and may modify drug action. Table 1 .
Enantiomer Interactions of S-and R-Omeprazole on P450s 785
Although most chiral drugs are administered as the racemate, a few examples of interactions between enantiomers have been described previously (Kroemer et al., 1996) .
In this study, the v R /v S (or v R app /v S app ) ratios of the metabolic reactions of OME enantiomers showed different profiles over the concentration range studied. According to MichaelisMenten kinetics and the competitive interaction model, this ratio of the competing enantiomers can reflect the stereoselectivity and the affinity of the enantiomers to the enzymes. At low substrate concentration, this ratio is close to the ratio of the true CL int,R /CL int,S by both individual enantiomers and the racemate and shows the enzyme stereoselectivity of the reaction. When the ratio is not changing with the substrate concentration, it indicates that the two enantiomers have similar affinities to the enzymes (K m,R is similar to K m,S ) (e.g., v R app /v S app of the racemate is constant in rCYPs, where K m,R app ϭ K m,S app ). However, when the ratio is changing it suggests that the enantiomers have different affinities to one enzyme or that multiple enzymes are involved. In HLM, the v R /v S ratios of 5-hydroxylation for the individual enantiomers changed significantly in comparison with the other reactions over the studied concentration range, indicating that the difference in the enantiomers' affinities and stereoseletivities for the 5-hydroxylation enzymes is greater than for the other reactions.
In vivo studies on the stereoselectivity of the OME enantiomers have been reported previously. R-OME showed higher in vivo clearance than S-OME with R/S clearance ratios (CL/F) of 1.4 and 1.9 after oral dosing of racemic OME and the individual enantiomers, respectively, in CYP2C19 EMs (Tybring et al., 1997; Andersson et al., 2001 ). However, an opposite stereoselectivity was observed for CYP2C19 PMs in both studies, with a clearance ratio (R/S) of 0.6 after administration of racemic OME as well as the enantiomers individually. In our study, the total in vitro CL int values for R-OME were 1.5-and 2.2-fold higher than for S-OME in the incubations with the pseudoracemate and individual enantiomers, respectively, which are in agreement with those from the in vivo studies in EMs. In CYP2C19 PMs, the clearance of OME is significantly reduced and, in these subjects, CYP3A4 may function as an alternative OME-metabolizing enzyme (Tybring et al., 1997) . Our in vitro studies on rCYP3A4 showed that the R/S ratio of the total intrinsic clearance was 0.4 (Table 1) , which agrees with the value of 0.6 observed in vivo in CYP2C19 PMs.
Clinical data on racemic OME (20 mg) indicate that the plasma concentrations of OME sulfone were approximately 20 to 50% of those for 5-OH-OME in EMs after oral administration (Tybring et al., 1997; Furuta et al., 1999) . This in vivo observation is consistent with the in vitro microsomal data at OME racemate concentrations below 5 M, where CYP2C19 is the predominant enzyme involved. At high OME racemate concentration, the formation rate of OME sulfone is almost comparable with that of 5-hydroxylation, where the contribution of CYP3A4 is significant. For the individual incubation of S-OME in HLM, however, the relative formation rate of 5-OH-OME to that of the sulfone did not change significantly with increasing S-OME concentration. The sulfone is the major metabolite formed, with concentrations approximately 2-fold higher than those of 5-OH-OME in the S-OME range from 1 to 100 M. This result is in good agreement with an in vivo study, where the plasma concentration (C max ) of OME sulfone was approximately 2.5-fold that of 5-OH-OME after a single oral dose of 40 mg of esomeprazole (Hassan-Alin et al., 2000) . This finding suggests that the metabolism of S-OME is less dependent on CYP2C19.
The inhibition potency of R-OME on the 5Ј-O-demethylation and 5-hydroxylation of S-OME was greater in rCYP2C19 than in HLM, whereas no such difference was seen for the inhibition by S-OME on the 5Ј-O-demethylation and 5-hydroxylation of R-OME. An explanation for this difference in the inhibition pattern might be the higher contribution of CYP3A4 to 5Ј-O-demethylation and 5-hydroxylation of S-OME than R-OME in HLM. Figure 8 shows that CYP3A4 becomes increasingly important for S-OME 5-hydroxylation and 5Ј-O-demethylation when incubated with its antipode, as opposed to when incubated alone. Thus, when the metabolism of S-OME by CYP2C19 in HLM is inhibited by R-OME, the metabolism of S-OME is switched to CYP3A4, on which the inhibitory effect of R-OME is less significant. For R-OME, this difference between the relative contribution of enzymes when comparing racemate and enantiomers was not so significant.
The results presented in this study indicate that the enantiomers are competing for the same P450 isoforms, with evidence for 1) lower V max values for all four metabolic reactions when incubated as pseudoracemate compared with those for the individual enantiomers; 2) enzyme kinetics of the enantiomers in pseudoracemate that fit the model of competitive interaction between enantiomers; and 3) both enantiomers were shown to be competitive inhibitors of each other's metabolism. The phenomenon of mutual competition between the enantiomers for the active site(s) has been reported, e.g., the enantiomer interactions of propafenone 5-hydroxylation by CYP2D6 (Kroemer et al., 1991) , cisapride N-dealkylation by CYP3A4 (Desta et al., 2000) , and flurbiprofen 4Ј-hydroxylation by CYP2C9 (Tracy et al., 1995) . These in vitro studies may reflect an in vivo situation, in which stereoselective first-pass metabolism leads to a ratio of the enantiomers different from unity in the systemic circulation. As a consequence, the ratio of substrate to inhibitor in this system will vary with time. Such interactions may be of clinical relevance if, as in the case of propafenone, the enantiomers differ in terms of pharmacological potency, and therefore inhibition of metabolism of one enantiomer by its optical antipode may modulate the net pharmacological effect of the drug. In OME, for which the proton pump inhibiting properties of the enantiomers are equal, the knowledge of the pharmacokinetic properties for the single enantiomer versus those of the racemate is important for the understanding of the relationship between the given dose and the pharmacological effect.
The CYP2C19-dependent polymorphic metabolism of PPIs in humans is well known (McColl and Kennerley, 2002) . The exposure of S-OME, when administered alone, compared with the OME exposure after dosing with the racemate, is higher in EMs but lower in PMs. Thus, dosing of the pure S-isomer of OME contributes to a decreased interindividual variability between EMs and PMs. The in vivo and/or in vitro stereoselective metabolism of other PPIs such as pantoprazole (Tanaka et al., 1997 (Tanaka et al., , 2001 ) and lansoprazole (Katsuki et al., 1996 (Katsuki et al., , 2001 Kim et al., 2002) has also been reported. After doses of racemic pantoprazole, marked stereoselective disposition was observed only in CYP2C19 PMs with (ϩ)/(Ϫ) clear- ance ratios (CL/F) of 1.25 and 0.29 in EMs and PMs, respectively (Tanaka et al., 2001) . The clearance of (ϩ)-pantoprazole was suggested to be related to CYP2C19 to a greater extent than the disposition of the (Ϫ)-enantiomer, which is similar to the situation for OME. For lansoprazole, after racemate dosing, the R(ϩ)/S(Ϫ) clearance ratio of the enantiomers was not significantly different between EMs and PMs, with values of 0.15 and 0.19, respectively (Kim et al., 2002) . It was suggested that, unlike OME, the enantioselective disposition of lansoprazole is less influenced by CYP2C19 genetic polymorphism and that a likely contributing factor is its stereoselective protein binding. However, with the reported stereoselective metabolism of the pantoprazole and lansoprazole enantiomers, catalyzed by the same P450 isoforms as OME, these compounds may well exhibit enantiomer/enantiomer interactions similar to those of OME.
In conclusion, we have shown enantiomer/enantiomer interactions for the formation of four metabolites of R-and S-OME, i.e., 5-and 3-OH-OME, 5Ј-O-desmethylOME, and OME sulfone. The in vitro experiments demonstrated that the inhibition mechanism for these interactions is competitive and that the metabolism of R-and S-OME by CYP2C19 and CYP3A4 is stereoselective. Our analyses indicate that the enantiomer/enantiomer interaction does not significantly change the clearances of the enantiomers in the racemate compared with those of the individual enantiomers. With regard to the equal proton pump inhibiting properties of the OME enantiomers, one might expect the enantiomer/enantiomer interaction during OME racemate therapy to be of little pharmacodynamic relevance. However, our study suggests that the use of the pure S-enantiomer of OME should be favorable in clinical therapy, providing a clearer metabolic profile and better predictability regarding pharmacokinetics and efficacy in comparison with the racemate.
